[Systemic biological treatment in ophthalmology]

Area of Science:

• Ophthalmology
• Rheumatology
• Immunology

Background:

• Non-infectious uveitis can be an early indicator of systemic autoimmune disorders.
• Ocular manifestations may precede the diagnosis of multi-organ autoimmune diseases.

Observation:

• Three patients presented with distinct forms of non-infectious uveitis: Vogt-Koyanagi-Harada disease, sarcoidosis, and inflammatory bowel disease.
• Ocular symptoms were the initial presenting complaints in all cases, suggesting underlying systemic autoimmunity.

Findings:

• Systemic biological therapy with adalimumab was required to achieve sustained remission of uveitis.
• Adalimumab effectively managed both the ocular inflammation and the associated systemic autoimmune conditions.

Implications:

• Systemic adalimumab is crucial for managing immune-mediated non-infectious uveitis in ophthalmology.
• Early introduction of biological agents can preserve visual acuity and control systemic disease activity.
• This highlights the importance of a multidisciplinary approach in managing complex autoimmune uveitis cases.